To determine the prognostic relevance of non-regional lymph node (NRLN) metastases presenting synchronously with bone metastases in metastatic prostate cancer (mPCa) for guiding treatment decisions based on oligometastatic definitions.
Objective
To determine the prognostic relevance of non-regional lymph node (NRLN) metastases presenting synchronously with bone metastases in metastatic prostate cancer (mPCa) for guiding treatment decisions based on oligometastatic definitions.
Patients and Methods
Patients diagnosed with mPCa between 2004 and 2013 were identified from the Surveillance, Epidemiology and End Results database and were grouped by metastatic sites into only NRLN, only bone, bone + NRLN and other sites AE bone/NRLN metastases. Multivariate Cox and competing risk regression analyses were performed to compare the risks of all-cause mortality (ACM) and prostate cancer-specific mortality (PCSM) associated with bone + NRLN metastases before and after propensity-score matching to patients with only bone metastases. This was complemented with landmark and supplementary analyses.
Results
Of 17 167 patients with mPCa identified, 63.1% presented with only bone metastases, while bone and NRLN metastases co-occurred in 8.9% of the cohort. On multivariate analyses, after adjusting for potential confounders (clinical and sociodemographic), patients with bone + NRLN metastases had a significantly higher risk of ACM (hazard ratio [HR] 1.161, 95% confidence interval [CI] 1.084-1.243; P < 0.001) and PCSM (subdistribution HR 1.149, 95% CI 1.067-1.237; P < 0.001) compared with patients with only bone metastases. Landmark analyses limited to survivors of ≥6 and ≥12 months again showed a significantly increased risk of ACM for patients presenting with bone + NRLN metastases compared with patients with only bone metastases. In a subsequent 1:1 propensity-score-matched cohort of patients with bone + NRLN metastases and only bone metastases, the bone + NRLN group had higher multivariate-adjusted hazard rates for ACM (HR 1.202, 95% CI 1.102-1.311; P < 0.001) and PCSM (subdistribution HR 1.146, 95% CI 1.044-1.259; P = 0.004).
Introduction
Metastatic dissemination of prostate cancer (PCa) is a complex multi-step cascade, characterized by variable progression patterns and survival outcomes. The current reductionist approach, simplifying biological behaviour by categorizing treatment according to metastatic sites and enumeration, has proven successful to a degree, but persistent variations in outcomes and treatment responses remain unpredictable. Metastatic prostate cancer (mPCa) patients with bone or visceral metastases are reported to have a poor prognosis compared to those with non-regional lymph node (NRLN) metastases in isolation [1] [2] [3] . Based on these results, NRLN metastases in isolation can be considered a low-risk feature in patients with mPCa; however, a non-negligible proportion of patients present with concomitant NRLN and bone metastases [4] [5] [6] . Such patients were reported to have poor overall survival (OS) compared with patients with only bone metastases in the STAMPEDE and TAX 327 trials, indicating this as a high-risk feature [4, 6, 7] . This has led to uncertainty regarding inclusion or exclusion of NRLN metastases in prominent enumeration-based oligometastatic definitions [8] [9] [10] . A recent review reported that only two out of six studies and four out of 10 ongoing trials explicitly include NRLN metastases as an enumeration criterion [10] . Moreover, 'high-volume' disease definitions, as used in the CHAARTED, GETUG-15 and LATITUDE trials, do not consider NRLN metastases [11] [12] [13] .
The aforementioned trial results demonstrating adverse prognosis of patients with concomitant bone and NRLN metastases may be inferred but not directly extrapolated to a general population-based setting, as trials select patients who are generally younger and fitter overall. Thus, it is appropriate to explore the prognostic relevance of concomitant NRLN metastases in patients with bone metastases in a large nationwide population to evaluate their inclusion or exclusion for guiding treatment decisions based on oligometastatic definitions [11, 12, 14, 15] .
Patients and Methods

Data Source
The US National Cancer Institute-Surveillance, Epidemiology and End Results (SEER) database documents cancer incidence and mortality data from 18 cancer registries covering~28% of the US population. We used the November 2016 submission of this database to study the distribution of metastases at first presentation and correlate that with survival outcomes, thereby determining the prognostic relevance of concomitant bone and NRLN metastases in mPCa using collaborative staging variables [16] .
Study Cohort
We interrogated the data from 18 SEER registries using the SEER*Stat 8. and who were actively followed were included. Use of these variables returned a cohort of 17 199 patients. After this, we excluded 27 patients with metastatic site coded as 38 (M1b with no other information on distant metastasis), because it was not possible to discern the presence or absence of concomitant NRLN involvement in these patients. Additionally, we excluded five patients with missing information on census tract income and education. After all exclusions, the final study cohort comprised 17 167 men.
Sites of Metastases
The collaborative staging data collection system is a joint initiative sponsored by the AJCC to streamline staging data collection in cancer registries [17, 18] . The 'CS mets at dx (2004+)' variable in the SEER database includes information on metastatic sites at diagnosis. We used this variable to subclassify patients by metastatic site at diagnosis into four groups as follows: only NRLN metastases (codes: 11, 12, 20) ; only bone metastases (code: 30); bone + NRLN metastases (code: 35); and other sites AE bone/NRLN metastases (codes: 40, 50, 58, 55).
Covariates and Study Endpoints
We abstracted age at diagnosis, race, year of diagnosis, PSA level at diagnosis, Gleason score at diagnosis, T stage (derived AJCC T stage, 6th edition) and N stage (derived AJCC N stage, 6th edition), marital status and SEER registry for each patient. Race was classified as white, African-American, and other/ unknown. PSA was used as a categorical variable (<20, 20-49.9, 50-97.9, ≥98 ng/mL, or unknown), as the SEER database categorizes all PSA values ≥98 ng/mL into one category. Gleason score was determined from SEER collaborative staging site-specific factors 5-10 [19] . The highest available Gleason score was abstracted for each patient and categorized as ≤7, 8, 9, 10 or unknown. Additionally, as the SEER database began recording insurance status from 2007 onwards, we abstracted insurance status (insured, Medicaid, non-insured or unknown) for use in a supplementary analysis limited to patients diagnosed between 2007 and 2013.
Furthermore, as the SEER database does not provide individual patient-level socio-economic status (SES) we also obtained county-level SES indicators. We used county-level income (median household income) and education status (percentage of residents aged ≥25 years with at least a high school education) as proxies for SES by linking to the 2000 USA census, and included them as continuous variables [20] . The residential status of patients was also determined at the county level by linking to 2013 US Department of Agriculture rural-urban continuum codes, with patients living in a county of <20 000 residents classed as non-metropolitan and the remaining as living in a metropolitan area [21] .
The primary study endpoint was all-cause mortality (ACM), defined as the time from diagnosis until death from any cause, with patients alive at the end of the study period censored (31 December 2014). PCa-specific mortality (PCSM) was identified using the SEER-coded cause-specific mortality and evaluated as a secondary endpoint. Patients who died from any other cause were placed in the non-PCSM category.
Statistical Analyses
To compare baseline clinical and sociodemographic characteristics between patients with only bone metastases and bone + NRLN metastases, categorical variables and continuous variables were compared using the Pearson's chisquared and Mann-Whitney U-tests, respectively.
To evaluate the primary objective of comparing survival between patients with only bone metastases and bone + NRLN metastases, our statistical analyses comprised two sets of analyses. The first set of analyses compared the survival within the whole cohort. Survival was estimated using the Kaplan-Meier method and comparisons were performed using the log-rank test and unadjusted Cox models. Cox regression analysis was used to assess the risk of ACM, and PCSM was assessed using Fine and Gray competing risk regression with non-PCSM treated as a competing risk [22] . All multivariable models were adjusted for age, race, PSA, Gleason score, year of diagnosis, T stage, N stage, SEER registry, residence, income, education status and marital status. We then performed a sensitivity analysis to gauge the effect of a potential unmeasured confounder on the obtained hazard ratio (HR) of ACM for patients with bone + NRLN metastases from the multivariate Cox regression analysis [23, 24] . Additionally, to account for more favourable baseline prognosis of patients with only bone metastases, we conducted landmark analyses limited to patients surviving a minimum of ≥6 and ≥12 months from diagnosis. Furthermore, we also conducted two sets of supplementary multivariate analyses. As a large proportion of patients had unknown Gleason scores or PSA levels, we excluded these patients to rule out any missing data bias and repeated multivariate Cox and competing risk regression analyses as stated above. We also repeated multivariate Cox and competing risk regressions analyses by introducing insurance status as an additional covariate along with the other aforementioned covariates in a subset of patients diagnosed between 2007 and 2013.
We then explored the risk of ACM associated with bone + NRLN metastases using univariate Cox regression analyses in three pre-specified subgroups. First, we explored whether the magnitude of risk of ACM associated with bone + NRLN metastases differed significantly among patients with or without regional lymph node disease. Second, we stratified the cohort by year of diagnosis (2004-2009 vs 2010-2013 ).
This was done to exclude any possible heterogeneity attributable to a substantial change in the therapeutic landscape for castration-resistant mPCa (mCRPC) following 2010 with the introduction of newer life-prolonging drugs [25] . Third, to explore heterogeneity attributable to variances in data abstraction among different SEER registries, we grouped the SEER registries according to different Contract Health Service Delivery Area regions (Pacific Coast, South West, Northern Plains and Eastern; Table S1 ) and then evaluated the risk associated with ACM for patients with bone + NRLN metastases among these different regions.
In the second set of analyses, we first performed a 1:1 propensity-score matching to account for inherent differences observed in baseline characteristics [26] . Patients with bone + NRLN metastases were matched to patients with only bone metastases using the nearest-neighbour method without replacement on the logit of the propensity score (derived from age, race, year of diagnosis, Gleason score, PSA, T stage, N stage, SEER registry, marital status, residence, household income, education level). The caliper width used was 0.1 times the standard deviation of the propensity score logit [27] . After matching, the balance of covariates between the matched groups was checked [28] . We then repeated multivariate Cox and competing risk regression analyses for predicting ACM and PCSM, respectively.
Statistical analyses were carried out using R statistical package v.3.3.3 (R Project for Statistical Computing, http://www.rproject.org/) or STATA 13 (StataCorp, College Station, TX, USA). All tests were two-sided, with P values <0.05 taken to indicate statistical significance.
Results
Cohort Characteristics
We identified 17 167 men diagnosed with mPCa between 2004 and 2013. The majority of the patients presented with only bone metastases (63.1%). Concomitant involvement of NRLNs with bone metastases (bone + NRLN) occurred in 8.9% of patients with mPCa (Fig. S1 ). Patients with bone + NRLN metastases were significantly younger (median age 66 vs 71 years), had higher Gleason score (Gleason score 8-10 disease: 83.5% vs 74.5%), had a higher PSA level (≥98 ng/mL: 68.4% vs 51.5%), presented with a higher T stage (T stage 3-4: 38% vs 25.1%) and had greater involvement of regional lymph nodes (N1: 73% vs 17.5%) compared to patients with only bone metastases (all P values <0.05; Tables 1 and S2 ).
Survival Analyses in Overall Cohort
The mean and median follow-up times for the entire cohort were 65 (95% CI 64.4-66.2) and 63 months (95% CI 61.6-64.4), respectively. Kaplan-Meier analysis showed that Table 1 Baseline characteristics of patients with only bone metastases and bone + non-regional lymph node metastases in the overall cohort and propensity score-matched cohort. Gleason score, n (%) ≤7 Extended table with additional baseline socio-demographic characteristics are included in (Table S2) 
Unmeasured Confounder Sensitivity Analyses
A unmeasured confounder sensitivity analysis was conducted based on the adjusted HR of ACM for patients with bone + NRLN metastases compared to patients with bone metastasis (HR 1.161, 95% CI 1.084-1.243). This explored the extent of imbalance of a unmeasured confounder between the bone and bone + NRLN groups that would be necessary to affect the statistical significance of our results. For instance, for an unmeasured confounder such as number of bone metastasis ≥4 with a prevalence of ≥70% in the bone group and with an associated twofold increased risk of death (HR 2), the prevalence of ≥4 bone metastases in the bone + NRLN group would have to be ≤50% to influence the estimated HR enough to make the results nonsignificant (lower bound of 95% CI <1) and ≤40% to reverse the HR <1. Overall, the unmeasured confounder sensitivity analyses indicated that a marked difference in the prevalence of an unmeasured confounder associated with a modest risk of death (HR 1.25), or a modest imbalance in the prevalence of a potential unmeasured confounder associated with a high risk of death (HR 3.25), would be required to render our results insignificant (Table 3) .
Subgroup Analyses
Finally, subgroup analyses did not show any heterogeneity in increased risk of ACM associated with bone + NRLN metastases among patients with N1 (HR 1.322, 95% CI 1.193-1.464; P < 0.001) or N0 disease (HR 1.367, 95% CI 1.201-1.556; P < 0.001; interaction P value = 0.638 [ Fig. S2]) . Similarly, a significantly increased risk of ACM for patients with bone + NRLN metastases compared to patients with only bone metastases was demonstrated in patients diagnosed before (HR 1.237, 95% CI 1.138-1.344; P < 0.001) and after 2010 (HR 1.244, 95% CI 1.125-1.376; interaction P value = 0.912).
Subgroup analyses stratified by geographic regions showed that the patients with bone + NRLN metastases diagnosed within the southwest SEER registries (New Mexico and Utah) were at an increased nonsignificant risk of ACM compared to patients with only bone metastases (HR 1.320, 95% CI 0.930-1.873; P = 0.12). Similarly, patients with bone + NRLN metastases were at a nonsignificant increased risk of ACM (HR 1.213, 95% CI 1.0-1.471; P = 0.05) in the Northern Plains region (Detroit, Iowa). Overall, no significant heterogeneity was seen in increased risk of ACM associated with patients bone + NRLN metastases compared to patients with only bone metastases among different regions.
Propensity Score-Matched Cohort Analyses
A 1:1 propensity-score matching of patients with bone + NRLN metastases to patients with only bone metastases yielded a cohort of 3008 patients. Baseline characteristics were well balanced across all covariates in the matched cohort (Tables 1 and S2 ). Within this matched cohort, patients with bone + NRLN metastases had a significantly decreased median OS compared to patients with only bone metastases (24 vs 29 months; log-rank P < 0.001 [ Fig. 1]) . Furthermore, multivariate analyses again demonstrated an increased risk of ACM (HR 1.202, 95% CI 1.102-1.311; P < 0.001) and PCSM (subdistribution HR 1.146, 95% CI 1.044-1.259; P = 0.004) for patients with bone + NRLN metastases compared to patients with only bone metastases (Tables 2 and S5 ).
Discussion
Within this large, general population-based analysis of patients with PCa presenting with metastases at diagnosis, we report that the combination of metastatic sites has an important bearing on the natural history of the disease. This is exemplified by the increased risk of ACM and PCSM in patients presenting with coexisting NRLN and bone metastases as compared to patients with only bone metastases.
These findings have important implications for guiding oligometastatic definitions and decisions regarding the use of life-prolonging therapies, such as docetaxel or abiraterone acetate, in hormone-na€ ıve mPCa. Currently, there is an ongoing international debate regarding the definition and use of 'high-' and 'low-volume' radiological disease burden in directing combination systemic treatment [11] [12] [13] 29] . Highvolume disease at diagnosis currently indicates docetaxel treatment within the hormone-na€ ıve mPCa population in some countries [15] , based on the findings of the CHAARTED and GETUG-15 studies [11, 13] ; however, this view is not accepted universally following published data from the docetaxel containing arms of the STAMPEDE trial [14, [29] [30] [31] [32] , where there was no observed heterogeneity of effect. This clinical uncertainty is reflected in the recent Advanced Prostate Cancer Consensus Conference report in which 36% of PCa experts did not agree with the ACM, all-cause mortality; HR, hazard ratio; NRLN, non-regional lymph node; PCSM, prostate cancer-specific mortality; SEER, Surveillance, Epidemiology and End Results. *All HRs or subdistribution HRs displayed are for patients with bone + NRLN metastases (patients with only bone metastases is the reference category).
'CHAARTED' definition and 14% felt that they would administer docetaxel and androgen deprivation therapy to patients with any metastatic disease when first presenting, whether 'low' or 'high' volume [8] . Even if the high/low hypothesis is supported by further data from ongoing studies, there is a fundamental flaw in this 'CHAARTED'-based approach to patients who present with metastases both in NRLNs and bone, but whose bone metastases number falls below the defined number of 4 (or 3 in the LATITUDE trial) [11, 12] . This is because the NRLN status in the context of bone metastases is not currently acknowledged in highvolume 'CHAARTED-type' definitions; therefore, volumetric definitions as used in some other ongoing clinical trials which include NRLN in their enumeration criteria might be more appropriate to guide risk stratification in mPCa [10] . More recently, a panel of advanced PCa imaging experts also recommended (85% consensus) that enumeration-based oligometastatic definitions should be pooled over NRLN and bone metastases [9] . Our results support this recommendation.
Findings similar to those of the present study have also been previously reported within the STAMPEDE and TAX327 trials [4, 6] . Evaluation of data from 917 patients enrolled within the control arm of the STAMPEDE trial showed that patients with bone + soft tissue metastases (mainly NRLN) have a worse 2-year OS (75% vs 60%) compared to patients with only bone metastases. Our findings are similar to these, and add a greater reassurance that these outcomes also apply to a 'real-world' non-trial population. The larger scale of the investigation also provides a high degree of confidence that the effect reported herein is a true phenomenon. Similarly, Pond et al. [6] compared OS in patients with mCRPC with bone + NRLN metastases to patients with only bone metastases within the TAX327 trial. They also reported an increased risk of death in patients with bone + NRLN metastases compared to patients with only bone metastases (HR 1.37, 95% CI 1.17-1.6) for the overall cohort after adjusting for treatment received, baseline pain, Karnofsky performance score, prior progression type, PSA, tumour grade, alkaline phosphatase level and haemoglobin level. Furthermore, a recent SEER Medicare analysis of 4 404 patients with mPCa was conducted to evaluate the relationship of metastatic sites to skeletal-related events [33] . This study reported that patients with bone + NRLN metastases have a higher probability of developing skeletalrelated events compared with patients with only bone metastases (52% vs 46%). Taken together these findings suggest that bone + NRLN metastases is an aggressive mPCa phenotype at presentation and continues to be so in the mCRPC setting.
The present findings also provide an interesting insight into the natural history of PCa.
We have yet to explain from a biomolecular perspective why the combined interaction associated with NRLN and bone metastases shows a significant reduction in OS when compared with bone metastases alone; however, in the present cohort, patients with bone + NRLN metastases were younger than those with only bone metastases. Furthermore, no heterogeneity in effect was seen between patients with N0 or N1 disease, and N1 disease status was not a significant predictor in our multivariate models; therefore, this disease phenotype at presentation may represent an aggressive mPCa phenotype wherein distant haematogenous and lymphatic spread occur simultaneously or in quick succession. Further evaluation of metastatic dissemination patterns in the hormone-na€ ıve setting are warranted to evaluate linear progression or metastasis to metastasis spread as reported in mCRPC [34, 35] .
The results of the present study should be interpreted within the context of the limitations pertaining to data obtained from SEER [36] . The identification of metastatic sites is based on the best available information (clinical/imaging/ pathological) in the SEER registries; therefore, a great share of this information in living patients can be considered to be obtained from conventional imaging and a detection bias attributable to lower sensitivity cannot be excluded. Current oligometastatic definitions as used in the CHAARTED, GETUG-15 and LATITUDE studies are based on conventional imaging ( 99m Tc-methylene diphosphonate planar or single-photon-emission CT bone scan and cross-sectional CT/MRI of the pelvis and abdomen AE chest). These conventional imaging techniques have a lower sensitivity in detecting metastases compared with emerging imaging techniques, such as Na 18 F-PET, 68 Ga-PSMA-11 positronemission tomography and whole-body diffusion-weighted MRI. With increasing adoption of emerging imaging techniques, a stage migration (very-high-risk M0 to oligometastatic M1) can be foreseen. Further evaluation of metastatic site and enumeration-based definitions using emerging techniques is therefore warranted in future clinical trials. Other variables regarding metastatic burden such as number, size and location, which are being used to further refine risk stratification in the metastatic setting are not recorded in the SEER database; however, our sensitivity analyses suggested that a moderate imbalance in metastatic site prevalence would not affect our conclusions. We also recognize that a number of other additional prognostic variables, such as performance status and alkaline phosphatase level, are not recorded in the SEER database and could not be included in the analyses, limiting our ability to draw conclusions. Finally, data on systemic therapies were unavailable; however, androgen deprivation therapy remained the 'gold standard' for patients with de novo mPCa for the study duration. Furthermore, a subgroup analysis before and after 2010 did not reveal any heterogeneity, ruling out a potential bias favouring improved survival of patients with only bone metastases after 2010 in the mCRPC setting.
In conclusion, the combination of NRLN with bone metastases is a poor prognostic marker in comparison with bone metastases alone. This should be considered as a highrisk feature within metastatic volume-stratified definitions to improve the accuracy of disease volume-based decisions when considering combination treatments in hormone-na€ ıve mPCa. The mechanisms explaining this differential biological effect are poorly understood and further investigations are required to improve the basic scientific understanding of hormonena€ ıve metastatic phenotypes. Prospective volumetric disease quantification, with a precise recording of metastatic sites and burden, should be considered as part of future trial designs within hormone-na€ ıve mPCa treatment.
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